[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.167.142.229. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
July 1999

The Role of Mycophenolate Mofetil in the Management of Pemphigus—Reply

Author Affiliations

Not Available

Arch Dermatol. 1999;135(7):854. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-135-7-dlt0799

In reply

We greatly appreciate the comment by Nousari and Anhalt concerning our article published in the ARCHIVES.

We agree with the authors that the final and optimal dosage of mycophenolate mofetil for the treatment of autoimmune diseases, such as pemphigus, still needs to be defined. The dosage of 2 g/d that we suggested may be too low to benefit certain patients with severe disease, although, in our hands, this dosage usually induced remissions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×